B of A Securities Downgrades Rhythm Pharmaceuticals (RYTM)
Fintel reports that on May 8, 2024, B of A Securities downgraded their outlook for Rhythm Pharmaceuticals (NasdaqGM:RYTM) from Buy to Neutral. Analyst Price Forecast Suggests 52.94% Upside As of May 2, 2024, the average one-year price target for Rhythm...
Fintel